Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
The purpose of this study is to collect samples for the purpose of developing a prenatal aneuploid test using circulating cell free fetal (ccff) nucleic acid from blood samples from pregnant women who have a high-risk pregnancy undergoing invasive prenatal diagnosis by chorionic villus sampling (CVS) and/or genetic amniocentesis. The results of the ccff aneuploid test will be compared to the chromosomal analysis obtained via CVS or amniocentesis.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00971334
Show 35 Study Locations
|Study Director:||Allan T Bombard, MD||Sequenom, Inc.|